Akash Saini

Ph.D., Manager, China In-Depth, Biopharma Insights

Mainland China’s anticipated biosimilar boom – potential and key drivers of the market

The market of major biologics in Mainland China has tripled since 2017, with the potential to grow five-fold over the next ten years – which could drive biosimilars growth. Clarivate expert Akash Saini discusses this market’s potential and key drivers.    The approval of Shanghai Henlius Biotech’s HLX01—a biosimilar of rituximab (Roche’s MabThera)—in February 2019 […]